Fly News Breaks for February 27, 2019
Feb 27, 2019 | 05:20 EDT
Piper Jaffray analyst Danielle Brill raised her price target for GW Pharmaceuticals to $185 saying the Epidiolex launch is off to a "very strong start" and still gaining momentum. Management commentary indicates the launch is "living up to the hype," Brill tells investors in a post-earnings research note. Further, she believes GW has the infrastructure in place to meet high demand. The analyst reiterates an Overweight rating on the shares.
News For GWPH From the Last 2 Days
There are no results for your query GWPH